The Patent Finder

Bioversys AG

23 patents currently held · Updated Nov 21, 2026
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5
Ending by 2030
Jul 2030
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Mar 26, 2027
    The maintenance fee for Antibiotic Combination Therapies (US 11,766,425) comes due Mar 26, 2027. Unpaid by Sep 27, 2027, it lapses early.
  • 1 fee due May 24, 2027
    The maintenance fee for Antimicrobial Compounds and Methods of Making and Using the Same (US 9,193,731) comes due May 24, 2027. Unpaid by Nov 24, 2027, it lapses early.
  • 2 fees due Jun 5 to 29, 2027 · next Jun 5
  • 1 fee due Aug 20, 2027
    The maintenance fee for Rifabutin treatment methods, uses, and compositions (US 11,903,934) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
  • 1 fee due Oct 30, 2027
    The maintenance fee for Novel Compounds (US 11,969,423) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,912,329Composition for Treatment of Tuberculosis
In force
 · High confidence
In forceHigh confidence
US 9,193,731Antimicrobial Compounds and Methods of Making and Using the Same
In force
 · High confidence
In forceHigh confidence
US 9,221,827Antimicrobial Compounds and Methods of Making and Using the Same
In force
 · High confidence
In forceHigh confidence
US 11,999,739Antimicrobials Methods of Making and Using the Same
In force
 · High confidence
In forceHigh confidence
US 12,234,238Antimicrobial Compounds and Methods of Making and Using the Same
In force
 · High confidence
In forceHigh confidence
US 9,682,079Composition for treatment of pathogens that are resistant to tetracyclines
In force
 · USPTO record
In forceUSPTO record
US 10,815,238Antimicrobial Compounds and Methods of Making and Using the Same
In force
 · High confidence
In forceHigh confidence
US 10,934,295Antimicrobials and Methods of Making and Using Same
In force
 · High confidence
In forceHigh confidence
US 11,253,499Novel Compounds
In force
 · High confidence
In forceHigh confidence
US 11,254,689Novel Compounds
In force
 · High confidence
In forceHigh confidence
10 of 23 patents shown.
Pro members see all 23.
Pro members: see all 23 patents
Also on record, not counted in the 23: 3 patents in force now held by others · 13 lapsed for an unpaid fee · 2 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

8 pending · 4 abandoned · 3 no status recorded

Showing 1 to 10 of 15, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
19/292,217Aug 6, 2025No status recorded
19/181,189Purification of Rifabutin FormulationsApr 16, 2025Pending
19/088,662Rifabutin Treatment Methods, Uses, and CompositionsMar 24, 2025Pending
18/649,196Novel CompoundsApr 29, 2024Abandoned
18/876,5513-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DerivativesJun 26, 2023Pending
18/875,3838-HETEROCYCLIC-3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE Derivatives as Anti-BacterialsJun 26, 2023Pending
18/855,839Rifabutin Analogs for the Treatment of DiseaseApr 6, 2023Pending
18/833,285Rifamycin Derivatives for the Treatment of DiseasesJan 27, 2023Pending
18/722,156Rifabutin Analogs for the Treatment of DiseaseDec 21, 2022Pending
17/978,647Antibiotic Combination TherapiesNov 1, 2022Abandoned
10 of 15 applications shown.
Pro members see all 15 published applications.
Pro members: see all 15 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited